Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described benzoselenazepine compounds reported to be useful for the respiratory syncytial virus (RSV) infection.
Researchers from Nanjing Chengshi (TheraRNA) Biomedical Technology Co. Ltd. and collaborators have developed a novel ionizable lipid, C14-192, that features a 3-oxo-polyamine head group.
Appili Therapeutics Inc. and its partner Vitalex Biosciences LLC have announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded up to $40 million in funding to support the development of VXV-01, a vaccine aimed at protecting against invasive fungal infections.
Human rhinovirus (HRV) is the most frequent cause of upper respiratory infections and a key trigger of asthma exacerbations. No effective anti-HRV therapies exist, and vaccine efforts have been unsuccessful due to its extreme genetic and antigenic diversity, with over 160 known serotypes.
Enanta Pharmaceuticals Inc.’s phase IIb study of zelicapavir missed its primary endpoint in treating respiratory syncytial virus (RSV) but mined enough positive results to get the company to talk about advancing the once-daily oral treatment into further, larger studies.
Around the globe, fungal infections affect more than 1 billion people and account for several million deaths every year. They pose a particular problem in low- and middle-income countries, where antifungal drugs may be less available and, even if available, may prove ineffective because of fungal resistance. These considerations highlight the need for a next generation of antifungals.
Phase Scientific International Ltd. launched China’s largest clinical study for urine-based cervical cancer screening. If successful, the blood-based test could be the first non-invasive test for HPV.
In what represents the first filing to have emerged in the name of Cellect Laboratories Inc., one of the start-up’s co-founders, Claire Theresa Murphy, describes their development of a non-invasive screening method that could one day replace the Pap test.
Globally, over half of people living with HIV are women. But in clinical cure trials, they make up only about 20% of participants. And that gender imbalance is causing researchers to miss out on ways to improve cure strategies. Because women’s immune systems appear to be better at controlling HIV infection in a way that silences the reservoir – the provirus integrated into host cells in infected persons.
Breaking with its long-held, oft-recited mantra that observational studies are great for generating hypotheses but not as evidence for approval, the U.S. FDA is initiating the approval of leucovorin calcium tablets for patients with cerebral folate deficiency, a neurological condition that affects folate transfer into the brain.
RSS
